Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Male Urogenital Diseases 1Genital Diseases, Male 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

Cetuximab 44Oxaliplatin 39Irinotecan 38Fluorouracil 36Capecitabine 36pembrolizumab 35Leucovorin 35Bevacizumab 35Nivolumab 21Gemcitabine 17regorafenib 13Panitumumab 12IFL protocol 12Folfox protocol 12Cyclophosphamide 12Pemetrexed 11Cisplatin 11tislelizumab 9Paclitaxel 9HMPL-013 9Carboplatin 9130-nm albumin-bound paclitaxel 8durvalumab 7Specimen Handling 7Docetaxel 7trametinib 6Trifluridine 6Ipilimumab 6Drug Therapy 6trifluridine tipiracil drug combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Neoplasms × gedatolisib × Clear all
NCT01937715 2016-08-18

A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Pfizer

Phase 1/2 Terminated
18 enrolled 23 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡